Navigation Links
AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
Date:6/12/2008

AMSTERDAM, June 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has concluded enrollment and treated the last patient in the pivotal trial for it's lead product AMT-011 (Glybera(R)) for Hyperlipoproteinemia, a seriously debilitating and potentially lethal disease. After recent preparatory meetings with the rapporteur countries Germany and the United Kingdom of the European Medicines Agency (EMEA), AMT expects to file the Marketing Authorization Dossier with EMEA not later than the fourth quarter of 2008.

AMT has developed AMT-011 as a cure for patients with the rare genetic disorder Hyperlipoproteinemia (HPL) type I, also known as LPL-deficiency. These patients have extremely high fat levels in their blood resulting in recurrent and potentially lethal pancreatitis as well as an increased risk of cardiovascular complications and diabetes. Because of a defective gene HPL-patients do not produce an enzyme that normally breaks down fats in the blood. Currently, there is no effective treatment or cure for this seriously debilitating and potentially lethal disease.

AMT-011 is a gene therapy product designed to insert a healthy gene into the patient's body to replace the defective gene. The product is administered by a series of injections into muscle tissue after which the body starts to make the missing enzyme again. The advantage of this therapy is its potential to cure a disease instead of just treating the symptoms. AMT expects to finish the ongoing clinical trial with AMT-011 according to plan.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Synbiotics Corporation Announces Human Submission for FluDetect(R)
3. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
4. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
5. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
6. Indevus Announces Submission of New Drug Application
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
10. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
11. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...0 Radius Health ("Radius") announc...ion to its second institutional financing round, i...on and the total amount raised since the company,s...tional investors participated in the financing, le...PM Capital, The Wellcome Trust, HealthCare Venture...
(Date:11/20/2008)...ire-FirstCall/ -- PAREXEL International Corporatio...tical services provider, today announced that it h...atory consulting and clinical research capabilitie...ow has locations throughout five important biophar...clude Argentina, Brazil, Chile, and Mexico. This e...
(Date:11/19/2008)...PRNewswire/ -- Posit Science Corporation,research...for Neuroscience,Annual Conference in Washington,...may benefit Baby Boomers. The computerized brain ...adaptive exercises that target auditory and,langu...generalized,improvements in cognition by improvin...
(Date:11/19/2008)...t achieve statistical significance , , ISEL...os Corporation (Nasdaq: PARS ) today announced r...ical NanoEmulsion (NE) drug delivery technology fo..., The multi-center, randomized, double-blinded,... efficacy of the Company,s 3% Diclofenac Diethanol...
Breaking Medicine Technology:Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2New Questions Raised About Lung Cancer Screening 26945 1New Questions Raised About Lung Cancer Screening 26945 2New Questions Raised About Lung Cancer Screening 26945 3SCAN Health Plan Arizona Announces Its 2009 MAPD Benefits for Maricopa County 26942 1SCAN Health Plan Arizona Announces Its 2009 MAPD Benefits for Maricopa County 26942 2Small Animal Imaging Market 3A Biospace Lab Wins Frost 26 Sullivan Accolade for Its Successful Product Line Strategy 8030 1Small Animal Imaging Market 3A Biospace Lab Wins Frost 26 Sullivan Accolade for Its Successful Product Line Strategy 8030 2Small Animal Imaging Market 3A Biospace Lab Wins Frost 26 Sullivan Accolade for Its Successful Product Line Strategy 8030 3Small Animal Imaging Market 3A Biospace Lab Wins Frost 26 Sullivan Accolade for Its Successful Product Line Strategy 8030 4Acupressure calms children before surgery 26939 1Acupressure calms children before surgery 26939 2
...ation for Cancer Research,annual meeting -, PRINCE...-,Medarex, Inc. today presented preclinical data d...separate studies exploring the,efficacy and safety...ody-drug conjugates. CD19 and CD70 are both attrac...ch to cancer therapy. They are,expressed on cancer...
...e/ -- Researchers from the,Barbara Ann Karmanos Ca...dence today that an antibiotic typically prescribe...ventually treating,certain types of cancers. , Q. ...manos, and,members of his lab announced the findin... (CQ) appears to have an anti-tumor effect,in mice...
Other Medicine Technology:Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 2Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 3Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 4Alzheimer's Drug Shows Promise in Fighting Cancer 2
(Date:11/21/2008)...xperiments in mice find running increases producti... 21 (HealthDay News) -- In experiments in mice, ex...ction of brain stem cells usually seen with aging,...e restoration of the brain,s ability to stave off ...estore a neurochemical that is essential for the p...
(Date:11/21/2008)...ALLAS, Nov. 21 In a statewide surv...Texas Institute for Surgery at Presbyterian Hospit...s 2008 annual listing of " Super Doctors ." , ...work with Key Professional Media, Inc. to survey m...tate of Texas to ask, "If you needed medical care,...
(Date:11/21/2008)...EW ROCHELLE, N.Y., Nov. 21 A prest...lthcare providers will gather in Williamsburg, VA ...learn practical, clinical information on cutting-e...ures, and innovative research advances that impact...ation, and registration information is available a...
(Date:11/21/2008)...OSTON, Nov. 21 Innerscope Research...rm specializing in Emotional Response Measurement,...ves who will strengthen the,company,s research an...itiatives. , The three appointments, who de...Geoffrey Gill as Chief Financial Officer and Vice ...
Breaking Medicine News(10 mins):Health News:Exercise Keeps the Brain Young 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2
...ing them reason to attempt suicide, according to a...on at Auckland University and its results have bee... Health. It revealed that 34 per cent of young peo...t about killing themselves while 13 per cent had a...
...t synacthen, which when injected simulates the bod...id. This is// most common in sports where sports c...ncing tool. Synacthen and injecting performance en...r than medical treatment is banned. Though some ...
...rtheastern state of Meghalaya is encouraging mothe...ing its population to two// million, its chieftain...l (KHADC), a constitutional body to protect and pr... culture, is worried that the state's Khasi and th...
... November 15 and will continue till December 31, d...t program was started in 2006 for senior citizens ... reduce prescription drug costs. The benefits of ... 2007 during which time citizens who enrolled for ...
Other Medicine News:Health News:Sports Cheats Beware - New Test To Detect Synacthen Found 2Health News:Cash Rewards for Meghalaya Tribes to Encourage Baby Boom 2
The 15 and 18 Sony Flat Screen Monitors with articulating arm can be used in conjunction with existing surgical monitors or as replacements.
Colour video monitors.
The A3 3-Chip Camera includes digital processing, seamless autoshutter, industry-leading reliability, white balance with memory function, ease of operation, and a 2 year warranty.
Camera and light source in one compact "Plug-and-Play" device.
Medicine Products: